Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids

Recruiting

Phase 1

Phase 2

Ruxolitinib, uhCG/EGF, CorticosteroidsRuxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids

Sponsor:

Masonic Cancer Center, University of Minnesota

Code:

NCT05123040

Conditions

Acute-graft-versus-host Disease

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Interventions

Ruxolitinib 10 MG Oral Tablet

hCG

Corticosteroids

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-10-10. This information was provided to ClinicalTrials.gov by Masonic Cancer Center, University of Minnesota on 2024-10-21.